BCM
PVLA

BlueCrest Capital Management’s Palvella Therapeutics PVLA Stock Holding History

BlueCrest Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,000
Closed -$2.49M – 356
2026
Q1 		$2.49M Buy
+20,000
New +$2.09M 0.15% 129

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

BlueCrest Capital Management's PVLA Position: Q2 2026 in Review

BlueCrest Capital Management sold out of Palvella Therapeutics (PVLA) in Q2 2026, closing a stake of 20,000 shares — an estimated $2.49M sold.

BlueCrest Capital Management first reported a position in PVLA in Q1 2026 and held it in 1 quarter. The position peaked at $2.49M in Q1 2026. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • BlueCrest Capital Management reported no remaining Palvella Therapeutics position as of Q2 2026 after selling out during the quarter.
  • BlueCrest Capital Management sold 20,000 Palvella Therapeutics shares in Q2 2026, an estimated $2.49M.
  • BlueCrest Capital Management first reported a position in Palvella Therapeutics in Q1 2026 and held it in 1 quarter.
  • BlueCrest Capital Management's Palvella Therapeutics position peaked at $2.49M in Q1 2026.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on BlueCrest Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.